Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study

by Alex C. Spyropoulos MD, Concetta Lipardi MD, PhD, Jianfeng Xu PhD, Wentao Lu PhD, Eunyoung Suh PhD, Zhong Yuan MD, PhD, Bennett Levitan MD, PhD, Chiara Sugarmann BSN, MSHS, Yoriko De Sanctis MS, Theodore E. Spiro MD, Elliot S. Barnathan MD, Gary E. Raskob PhD
Published 2019-11-01